Kiromic BioPharma, Beverly Hills Cancer Center to Partner on Clinical Trials
Treatment facility to be the first to evaluate Deltacel for patients with non-small cell lung cancer.
Kiromic BioPharma announced that it has agreed to terms for Beverly Hills Cancer Center (BHCC) to serve as the inaugural clinical site for the evaluation of Deltacel (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, gamma delta t-cell (GDT) therapy, in patients with non-small cell lung cancer. BHCC includes a radiation oncology center, an infusion center, a full-service diagnostic imaging center (featuring MRI, CT, PET/CT), a diagnostic laboratory, and has previously conducted multiple clinical trials across multiple cancer types.
“As our clinical research program embarks on this groundbreaking clinical journey, we envision a future where patients have access to pioneering therapies and renewed hope in their battle against cancer. For years, BHCC has remained at the forefront of medical excellence, continually seeking innovative approaches to redefine the future of cancer treatment. We are very excited about this collaboration with Kiromic, a very forward-thinking and innovative company, and about this new therapeutic approach and the potential to contribute to science with the ultimate goal of improving the lives of cancer patients worldwide,” said Afshin Eli Gabayan, MD, medical director, principal investigator, Beverly Hills Cancer Center and Assistant Clinical Professor at UCLA-David Geffen School of Medicine.
Reference: Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement. BusinessWire. October 23, 2023. Accessed October 23, 2023. https://www.businesswire.com/news/home/20231023260123/en/Kiromic-BioPharma-and-Beverly-Hills-Cancer-Center-Enter-Clinical-Trial-Agreement
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
